Abelacimab, formerly known as MAA868, represents a novel approach to preventing thrombosis. This antiplatelet agent is a selective monoclonal antibody that inhibits the integrin αIIbβ3, a essential player in platelet https://www.targetmol.com/compound/abelacimab